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Humanin (HN) is 24-amino acid mitochondria-associated peptide. Since its initial discovery
over a decade ago, a role for HN has been reported in many biological processes such as
apoptosis, cell survival, substrate metabolism, inflammatory response, and response to
stressors such as oxidative stress, ischemia, and starvation. HN and its potent analogs have
been shown to have beneficial effects in many age-related diseases including Alzheimer’s
disease, stroke, diabetes, myocardial ischemia and reperfusion, atherosclerosis, amy-
otrophic lateral sclerosis, and certain types of cancer both in vitro and in vivo. More recently,
an association between HN levels, growth hormone/insulin-like growth factor-1 (GH/IGF
axis), and life span was demonstrated using various mouse models with mutations in the
GH/IGF axis. The goal of this review is to summarize the current understanding of the role
of HN in aging and age-related diseases.
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INTRODUCTION
Humanin (HN) is a novel, 24-amino acid polypeptide with proven
effects on cell survival, metabolism, response to stressors, and
inflammation in vivo and in vitro. It was discovered in 2001, using a
modified “death-trap” screening, in the unaffected occipital brain
of a patient with sporadic Alzheimer’s disease (AD) (1). Since
then, it has been identified in a wide range of tissues including
testes, colon, hypothalamus, heart, liver, skeletal muscle, kidney,
and vascular wall (2–6). Levels of HN are measurable in plasma,
cerebrospinal fluid (CSF), and seminal fluid indicating that it is a
secreted protein (4, 7–9), though it is still unclear which tissue(s)
contributes to the circulating HN pool.
Humanin is believed to be encoded from a small open read-
ing frame (ORF) in the mitochondrial (mt) DNA within the 16S
ribosomal RNA coding region. However, there are mitochondrial
pseudogenes within the nuclear DNA sequences with great resem-
blance to HN-encoding small ORF (10). The site of translation of
HN has not been fully identified yet and the length of HN mole-
cule would differ based on the site of translation. Because of the
differences in translational machinery between the mitochondria
and the cytosol, it will be a 21 amino acid peptide if translation
occurs in mitochondria, while cytoplasmic translation will yield
a 24-amino acid long polypeptide. Both 21 and 24-amino acid
peptides are biologically functional proteins (11, 12). A rat cDNA
encoding a secreted peptide homologous to HN, named Rattin
has also been identified, indicating the existence of HN in other
species (13). Indeed, Guo et al. reported that cDNAs identical or
similar to the ORF for HN exist in plants, nematodes, rats, mice,
and other species (14).
It is hypothesized that HN is a part of the “retrograde signal-
ing” – a vital communication process between mitochondria and
nuclear genome that maintains cellular homeostasis and integrity
(15). Very few retrograde signaling molecules and pathways have
been identified; including Ca2+, reactive oxygen species (ROS),
nitric oxide (NO), carbon monoxide (CO), and cytochrome c ; and
HN is heralded as the “harbinger” of other mitochondrial-derived
peptides by Lee et al. (15).
STRUCTURE OF HN
Humanin [Sequence: Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-
Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala
(MAPRGFSCLLLLTSEIDLPVKRRA)] is encoded from a 75 bp
ORF sequence within the 1,567 bp cDNA, which yields either a 21
or 24-amino acid polypeptide depending on the location of trans-
lation machinery. By binding to either intra-cellular molecules
[such as insulin-like growth factor-binding protein (IGFBP)-3,
Bax, Bak, or tBid] (14, 16–19) or membrane receptors (8, 20,
21), HN promotes cell survival in response to a variety of insults,
improves insulin sensitivity, increases glucose stimulated insulin
secretion (GSIS), as well as prevents oxidative stress-induced dam-
age due to ischemia/reperfusion (I/R), hypoxia, or starvation (refer
to related sections below for references).
Humanin has a positively charged N-terminal (Met-Ala-
Pro-Arg), central hydrophobic region (Gly-Phe-Ser-Cys-Leu-Leu-
Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu), and negatively charged C-
terminal (Pro-Val-Lys-Arg-Arg-Ala) (1, 22). Relatively short struc-
ture of HN has enabled researchers to identify the role of each
amino acid residue within the polypeptide through systematic
single amino acid substitution technique. Last three residues in
the C-terminal are accepted as non-essential because both 21 and
24-amino acid long peptides have indistinguishable intracellular
and extracellular effects (22).
Yamagishi et al. postulated that the entire HN peptide func-
tions as a signal peptide for extracellular secretion. They demon-
strated that the self-secretory function is lost when any of the
amino acid domains within the Leu9–Leu11, or Pro19–Val20
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structure was substituted for Arg (12). Furthermore, Leu10 was
identified as having a central role in this process, because Asp
substitution of this amino acid (L10A) but not Leu9 or Leu11
completely abolishes the extracellular secretion (12). With regards
to the neuro-protective function, Pro3 to Pro19 is termed as
“neuro-protective core domain,” and the amino acids Pro3, Ser7,
Cys8, Leu9, Leu12, Thr13, Ser14, and Pro19 within this domain
were found to be essential (12). Single amino acid substitution
of these positions to Ala to form P3A, S7A, C8A, L9A, L12A,
T13A, S14A, and P19A, respectively, completely abrogates the
neuro-protective effect of HN molecule, whereas, replacement of
Ser14 to Gly (S14G, HNG) results in increased cyto-protective
potency of HN over 1,000-fold (23). Replacement of Ser14 with
D-form Serine (D-Ser) residue also increases neuro-protective
function similar to HNG; whereas, D-Ser7 substitution does
not (24).
Ikonen et al. demonstrated that Phe6 and Lys21 are essential
sites for binding of HN to its interacting partner, IGFBP-3. While
Phe6 to Ala conversion (F6A) completely abolishes the interac-
tion of HN to IGFBP-3, Lys21 to Ala (L21A) conversion blocks the
interaction only at lower concentration of IGFBP-3 (16). Combi-
nation of the changes at the 6th (F6A) and 14th (S14G) positions
creates a more stable, non-IGFBP-3 binding molecule (HNGF6A),
which has the ability to modulate insulin action and increase GSIS
(25). Recently, Maftei et al. demonstrated that HN (5–15) directly
binds to 17–28 region of Amyloid β (Aβ) (1–40) using proteolytic
epitope excision and extraction, and affinity-metabolic syndrome
(MS) analyses (26). The inhibition of this region of Aβ previously
has been shown to effectively decrease aggregation of the neuro-
toxic amyloid fibrils, and associated cytotoxicity in vitro in human
neuroblastoma cell line, SH-SY5Y (27).
Nuclear magnetic resonance (NMR) and circular dichroism
(CD) studies have shown that the secondary structure of HN and
HNG is more disordered in water than in PBS, and the different
structure in PBS appears to be due to self-association of the pep-
tide (28). The self-association of HN into dimers and/or oligomers
appears to occur and seems to be required for biological activities
(12, 24). A complete list of the function of each amino acid and
the effect of substitution are summarized in Table 1.
Benaki et al. investigated the structure of synthetic HN in
aqueous and 30% 2,2,2-trifluoroethanol (TFE) solutions and
reported that in aqueous solution, HN exists predominantly in an
unstructured conformation in equilibrium with turn-like struc-
tures involving residues Gly5 to Leu10 and Glu15 to Leu18,
providing indication of nascent helix (29). In the less polar envi-
ronment of 30% TFE, HN readily adopts helical structure with
long-range order spanning residues Gly5 to Leu18 (29). Compar-
ative 3D modeling studies and topology predictions also support
the observation. These studies reveal the flexibility of HN mole-
cule in aqueous environment, which makes it free to interact with
possible receptors that mediate its action, but also the ability of
HN to acquire a helical conformation necessary for specific inter-
actions and/or passage through membranes (29). Another study
showed that HN is readily stabilized in an ordered helical con-
formation in the TFE/water mixture, but kept partly unfolded in
water (30).
HN SIGNALING PATHWAYS
Humanin exerts its diverse functions through binding to both
intracellular molecules and putative cell membrane receptors
(Figure 1). Guo et al. demonstrated that HN binds to Bcl-2-
associated X protein (Bax), a pro-apoptotic signaling peptide.
Utilizing yeast two-hybrid co-immunoprecipitation studies, the
authors demonstrated that wild type HN specifically binds to
inactive form of Bax, inhibits the conformational changes and
transfer of Bax from cytosol to the mitochondria, and thereby sup-
pressing cytochrome c release, an initiation step of apoptosis, and
inhibiting staurosporine-induced death (14). Another intracellu-
lar pro-apoptotic protein“BH3 interacting-domain death agonist”
(Bid), and its truncated form (tBid) were also shown to bind to
HN and contribute to its anti-apoptotic effect (19). Activation of
Bid involves proteolytic removal of its N-terminal and myristoy-
lation to form tBid, which then translocates to the mitochondria,
leading to the mitochondrial permeabilization and cytochrome
c release (31). HN does not block proteolysis of Bid nor pre-
vents the translocation of tBid to mitochondria, but rather inhibits
the association of tBid with Bax and as a consequence, prevents
tBid-induced oligomerization of Bax, and suppresses release of
cytochrome c. Furthermore, Ikonen et al. demonstrated that HN
binds to and modulates the pro-apoptotic function of IGFBP-
3, and regulates cell survival (16). Other intracellular molecules
that have been shown to bind to HN are actinin-4 (32), a tri-
partite motif protein TRIM11 (33), and M-phase phosphoprotein
8 (MPP8) (Figure 1) (34). Recently, a V-set and transmembrane
domain containing two like (VSTM2L) protein, was demonstrated
to co-localize with HN in distinct brain areas as well as in pri-
mary cultured neurons, and function as an antagonist of HN
(Figure 1) (35).
In terms of the extracellular signaling by HN, Ying et al.
reported that HN induces chemotaxis of human mononuclear
phagocytes by binding to human G protein-coupled formyl pep-
tide receptor-like-1 (FPRL-1) and its murine counterpart FPRL-2
(20). Interestingly, FPRL-1 and FPRL-2 are also functional recep-
tors for Amyloidβ (Aβ) 42, an important peptide in the pathophys-
iology of AD-related neuronal toxicity, suggesting that HN may
exert its neuro-protective effects also by competitively inhibiting
the access of FPRL-1 to Aβ 42 (20). This hypothesis was further
supported by Harada et al. who demonstrated that HN directly
binds to FPRL-1 and 2 receptors in Chinese hamster ovary cells
expressing the corresponding receptors after transfection (21).
On the contrary, Hashimoto et al. showed that HN exerts neuro-
protection against Aβ and activates signal transducer and activator
of transcription (STAT) 3 in F11 cells even after siRNA-mediated
disruption of FPR2, the mouse counterpart of FPRL-1 (36), sug-
gesting the existence of alternative receptor(s) of HN. In fact, they
discovered a tripartite cytokine-like receptor complex [belonging
to the interleukin (IL)-6 receptor family] comprising the ciliary
neurotrophic factor (CNTF) receptor, the IL-27 receptor WSX1,
and glycoprotein (gp)130, activation of which upregulates the
Janus Kinase (JAK) 2 and STAT-3 pathways (8). Based on these
findings, it is speculated that different cell types express differ-
ent cell membrane receptors to respond to HN (11). The signaling
pathways and binding partners of HN are summarized in Figure 1.
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Table 1 | Structure of HN peptide and role of individual amino acids.
Pos. Amino acid Function Effect of amino acid substitution
N-TERM
1 Met (M)
2 Ala (A)
3 Pro (P) Neuro-protection Pro3 to Ala (P3A) – abrogates neuro-protective function
4 Arg (R)
HYDROPHOBIC CORE REGION
5 Gly (G)
6 Phe (F) IGFBP-3 binding, Aβ binding Phe6 to Ala (F6A) – abrogates IGFBP-3 binding
7 Ser (S) Aβ protection Ser7 to Ala (S7A) – abrogates cyto-protective and
neuro-protective functions, and prevents dimerizationAβ binding
Dimerization
8 Cys (C) Neuro-protection Cys8 to Ala (C8A) – abrogates neuro-protective function
BAX, BAD, and tBID binding
9 Leu (L) Neuro-protection Leu9 to Arg (L9R) – Non-secretory, but retains function when
added into the mediumSecretion
Dimerization Leu9 Ala (L9A) – prevents dimerization and abrogates
neuro-protective function
10 Leu (L) Secretion Leu10 to Asp (L10D) – abrogates secretion
Leu10 to Arg (L10R) – abrogates secretion
11 Leu (L) Secretion Leu11 to Arg (L11R) – abrogates secretion
12 Leu (L) Neuro-protection Leu12 to Ala (L12A) – abrogates neuro-protective function
13 Thr (T) Neuro-protection Thr13 to Ala (T13A) – abrogates neuro-protective function
14 Ser (S) Neuro-protection Ser14 to Gly (S14G) increases cyto-protective potency over
1,000-fold. This isoform is active when monomeric
Ser14 to D-Ser increases potency
Ser14 to Ala (S14A) – abrogates neuro-protective function
15 Glu (E)
16 Ile (I)
17 Asp (D)
18 Leu (L)
C-TERM
19 Pro (P) Aβ protection Pro19 to Ala (P19A) – abrogates neuro-protective function
Secretion Pro19 to Arg (P19R) – abrogates secretion
20 Val (V) Secretion Val20 to Arg (V20A) – abrogates secretion
21 Lys (K) IGFBP-3 binding Lys21 to Ala (L21A) – blocks interaction at lower IGFBP-3
concentrations22 Arg (R) ?Non-essential
23 Arg (R) ?Non-essential
24 Ala (A) ?Non-essential
Bolded: neuro-protective core domain (NPCD).
Humanin has been shown to activate other signaling pathways
besides JAK2–STAT-3, including p38 mitogen-activated protein
kinases (p38MAPK) (in human K562 cells, primary rat neurons,
and mouse germ cells in vivo) (37, 38), AMP-activated protein
kinase (AMPK) (mouse cardiac I/R model in vivo) (3), insulin
signaling in vivo in mouse models (39–41), and ERK1/2 in vitro
(20). It is also reported that HN inhibits amyloid precursor pro-
tein (APP) induced c-Jun N-terminal kinase (JNK) activation and
thereby protects neuronal cells from apoptosis (42).
REGULATION OF HN
The endogenous regulation of HN under physiological condi-
tions is not yet established. We have shown that the circulating
levels of HN decrease with age in both human and mice (43).
A relationship between HN and GH/IGF axis was reported in
a recent publication. Long-lived, GH-deficient Ames mice (that
have decreased GH and IGF-1) displayed elevated HN lev-
els, while short-lived GH-transgenic mice (high GH and high
IGF-1) have reduced HN levels. This relationship was further
confirmed in mice and humans; treatment with GH or IGF-1
reduced circulating HN levels (44). Using LID mice (liver spe-
cific IGF-1 deletion model-where the GH levels are high, while
IGF-1 levels are low) and IGFBP-3 knock-out mice (where free
IGF-1 levels are high), the authors demonstrated that the lev-
els of HN are inversely proportional to circulating IGF-1 lev-
els. There is increased expression of HN in response to GH
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FIGURE 1 | Signaling pathways: HN exerts its function through both
extracellular receptors and intracellular binding partners. The proposed
extracellular receptors are trimeric receptor complex including CNTF, WSX1,
and GP130 and downstream JAK2–STAT-3 signaling pathway, and FPRL-1/2
G-protein-coupled receptors. HN directly binds to Aβ 17–28 and prevents
the interaction of Aβ42 with receptors. HN also binds to its intracellular
partners including IGFBP-3, Bax, tBid, MPP8, TRIM11, and actinin-4.
VSTM2L is an extracellular antagonist of HN.
and IGF-I in cultured rat Leydig cells between 10 and 40 days
of life but not at 2 months of age (6) suggesting a devel-
opmental regulation. Niikura et al. identified that HN inter-
acts with a putative E3 ubiquitin ligase TRIM11, which leads
to the degradation of HN through the proteasome pathway,
and regulation of the intracellular level of de novo synthesized
HN (33).
Endogenous up-regulation of HN has been demonstrated in
certain pathological states. It is shown that HN peptide level is
strongly increased in mitochondria and siderosomes in diffuse-
type of pigmented villonodular synovitis (45). Increase in HN
expression is also demonstrated in the muscles of patients with
chronic progressive external ophthalmoplegia compared to those
in control fibers (5). An increased HN expression level in skele-
tal muscles from patients with mitochondrial encephalomyopa-
thy with lactic acidosis and stroke-like episodes (MELAS) was
also reported (46). The authors suggested that the increase
in HN could be an initial compensation for the defects in
energy production in the affected muscle fibers; while fur-
ther progressive defects may ultimately lead to degenerative
ragged-red fibers. Our findings of increased intracellular lev-
els of HN after myocardial ischemia and reperfusion (MI-R)
and persistence as long as 24 h in mouse cardiac tissue (3)
also suggest a compensatory up-regulation of HN in stress
conditions.
ROLE OF HUMANIN IN AGE-RELATED DISEASES
The discovery of HN molecule and the demonstration of its
neuro-protective activity in AD inspired researchers from differ-
ent fields to study the potential role of HN in the pathophysiology
of other neurological and non-neurological diseases (1). To date,
HN and its analogs have been demonstrated to play a role in mul-
tiple diseases including type 2 diabetes (25, 43), cardiovascular
disease (CVD) (2, 3, 47), memory loss (48), amyotrophic lat-
eral sclerosis (ALS) (49), stroke (50), and inflammation (22, 51).
The mechanisms that are common to many of these age-related
diseases are oxidative stress (52) and mitochondrial dysfunction
(53). Mitochondria are major source of ROS, excess of which
can cause oxidative damage of cellular lipids, proteins, and DNA.
The accumulation of oxidative damage will result in decline of
mitochondrial function, which in turn leads to enhanced ROS
production (53). This vicious cycle can play a role in cellular dam-
age, apoptosis, and cellular senescence – contributing to aging and
age-related diseases. Indeed, oxidative stress is tightly linked to
multiple human diseases such as Parkinson’s disease (PD) (54),AD
(55), atherosclerosis (56), heart failure (57), myocardial infarction
(58), chronic inflammation (59), kidney disease (60), stroke (61),
cancers (62, 63), and many types of metabolic disorders (64, 65).
We and others have shown that HN plays critical roles in reduc-
ing oxidative stress (66–68). In this section, we will summarize
the current knowledge on the role of HN in various age-related
diseases.
HN AND NEUROLOGICAL DISEASES
ALZHEIMER’S DISEASE
Alzheimer’s disease is predicted to affect 1 in 85 people glob-
ally by 2050. Short-term memory loss and impairment of other
cognitive domains are clinical hallmarks of the disease; whereas,
cerebral cortical atrophy due to neuronal cell loss particularly in
the temporal–parietal lobes, hippocampus and to a lesser extent
in the frontal lobes, accumulation of extracellular senile plaques
made of amyloid-beta (Aβ) protein (cleavage product of APP), and
hyper-phosphorylation of the microtubule associated tau-protein
are the main imaging and pathophysiological markers (25, 50).
The mechanism of the Aβ induced neuronal cell death has not
yet fully elucidated; however, multiple groups have postulated the
presence of death receptors as the potential mechanism of such
insult [for review see Ref. (27)].
Role in AD has been on the main focus of HN-related research.
The effects of HN on AD-related pathology as well as functional
correlates have been tested in in vitro systems and in in vivo mouse
models. Hashimoto et al. demonstrated that HN suppresses neu-
ronal cell death induced by Aβ and three different types of familial
AD (FAD) genes including mutant APP, presenilin (PS)1, and PS2
(1). In addition, HN inhibits neurotoxicity by AD-relevant insults
induced by other FAD genes including A617G-APP, L648P-APP,
A246E-PS1, L286V-PS1, C410Y-PS1, and H163R-PS1 and other
Aβ peptides (Aβ 1–42 and Aβ 25–35) (1). They showed that
HN mediated suppression of the neuronal cell death induced by
K595N/M596L-APP (NL-APP) is not through the inhibition of
Aβ1-42 secretion but via the HN’s inhibitory action on intracellu-
lar toxicity triggered by NL-APP and Aβ (69). Furthermore, they
showed that secretion is required for the neuro-protective effects
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by using non-secreted biologically active point mutant HN ana-
log (L9R), which is retained in the cytoplasm and did not exert
any cyto-protection but was protective when added to the culture
medium (1). Tsukamoto et al. demonstrated that Aβ toxicity in the
neuronal cell line can be completely suppressed with HN via one
of the proposed death receptor, the 75-kDa neurotrophin recep-
tor (p75 NTR) (47–49). HN protects PC12 neuronal cells from
Aβ-induced viability loss and cell apoptosis, decreases mitochon-
drial membrane potential and prevents cytochrome c release from
mitochondria-key steps in apoptosis (70). A potent HN analog,
HNG, has been shown to not only inhibit the formation of the
Aβ1–42 fibrils but also cause disaggregation of the preformed fib-
rils, which provides novel evidence that HNG may have anti-Aβ
aggregation and anti-fibrillogenesis, as well as fibril-destabilizing
properties (71).
With intra-cerebro-ventricular (ICV) injection of HNG, Aβ-
induced impairment of short-term/spatial working memory was
prevented in vivo (72). Interestingly, intraperitoneal (IP) adminis-
tration of HNG also ameliorated behavioral deficits, and reduced
neuro-inflammatory responses and apoptosis induced by ICV
injection of aggregated Aβ 25–35 in mouse brain (73). In a subse-
quent study, the group showed that chronic treatment (3-month IP
injection) of HNG: (i) significantly improves spatial learning and
memory deficits, (ii) reduces Aβ plaque accumulation and insol-
uble Aβ concentrations, and (iii) decreases neuro-inflammatory
responses in middle-age APPswe/PS1dE9 mice, a double trans-
genic mouse model of AD over expressing APP, and mutant human
PS-1 in neurons. Similar pathological and functional improve-
ments were also demonstrated in APPswe, tauP310L, and PS-
1M146V triple transgenic mice following treatment with HNG.
Interestingly, in this model, though there was reduced Aβ accu-
mulation, no changes in tau phosphorylation levels were noted
(74). This suggests that the cyto-protective effect of HN is inde-
pendent of the phosphorylation and aggregation of tau-protein.
However, more direct and detailed studies are needed to character-
ize any potential effect of HN on tau-protein aggregation induced
memory loss and learning deficit (75). Novel HN delivery sys-
tem, using a transducible HN with an extended caspase-3 cleavage
sequence (tHN-C3), was shown to protect neurons against H2O2
and soluble Aβ42 induced cell death in vitro through binding to
Bax. Delivering HN through this system was also found to decrease
inflammatory cell infiltration, decrease apoptosis in neurons and
improve memory learning deficits in genetic (Tg2576) and Aβ42
induced AD mouse models, and protect rats from I/R induced
brain injury (76).
Currently, there is no definitive cure for AD (31). The mul-
tiple in vitro and in vivo studies showing that HN or its potent
analogs protect from AD-related neuronal cell death and func-
tional impairments, offer significant promise for a potential role
for HN as a new treatment approach to treat AD.
STROKE
Stroke [cerebrovascular accident (CVA)] was the second leading
cause of death worldwide according to World Health Organization
(WHO) report in 2012 (http://who.int/mediacentre/factsheets/
fs310/en/). CVA can be either ischemic or hemorrhagic; ischemic
subtype constitutes roughly 80% of the all strokes (77). The role
of HN has been studied in both ischemic and hemorrhagic types
of stroke in mouse models in vivo.
Humanin either alone or in combination with other neuro-
protective factors has been shown to offer protection in cerebral
I/R mice models in vivo. Xu et al. demonstrated that ICV infusion
of HNG resulted in smaller infarct volume, decreased number of
apoptotic neurons, and improved neurological function in mid-
dle cerebral artery occlusion induced I/R injury in mice (50). This
was associated with inhibition of ERK (a member of MAPK signal-
ing pathway) phosphorylation and poly (ADP-ribose) polymerase
(PARP) activity, a marker of caspase-3 activity (50). Same group
also showed that activation of PI3 kinase/Akt signaling pathway
is important in HNG’s neuro-protective function (40). Further-
more, they also showed that combination of treatment with HNG
and a necroptosis inhibitor necrostatin-1 (Nec-1) results in more
robust neuro-protection than HNG or Nec-1 alone on I/R induced
cerebral infarct (78). The synergistic effects of HNG and Nec-1 on
hypoxia induced neuronal cell death were also replicated in in vitro
experiments using cultured mouse primary cortical neurons (78).
Others reported that HN protects cortical neurons from I/R injury
through an increase in activity of superoxide dismutase (SOD)
(79). Wang et al. showed protective roles of HNG in a mouse
model of intracranial hemorrhage following IP administration
within 1 hour post injury (41); treatment with HNG resulted in
decreased brain edema, neuronal cell death, and injury volume
while improving neurological recovery.
The results of the limited studies are promising; however, more
studies are needed to better understand if HN can be used as a
therapeutic agent in the management of CVA.
OTHER NEUROLOGICAL CONDITIONS
Humanin was shown to play role in certain other neurological
diseases. HN was found to offer protective effect from Prion-
peptide (PrP) (118–135)-induced cell death, but not against PrP
(106–126). The reason for this selective protection is not clear
though the mechanistic differences between these two PrPs induc-
ing apoptosis could be a contributor (80). Mamiya et al. evaluated
the effects of the scopolamine-HBr induced impairment of spon-
taneous alternation behavior in mice using the Y-maze as an
index of short-term memory, and found that HNG reversed the
anti-cholinergic drug mediated impairment of the learning and
memory function in mice (48). In a recent publication, Cui et al.
reported that HN rescued cortical neurons from excitatory toxicity
caused by NMDA in a dose-dependent manner without interact-
ing with the receptors, and pointed to the potential role of its use
in preventing the damage caused by this pathway (81). However,
studies have shown that HN failed to protect against certain cyto-
toxicity including Q79, SOD mutants, etoposide, Fas, or basally
occurring death indicating specificity in action (1).
HN AND CARDIOVASCULAR DISEASES
Cardiovascular disease is the number one leading cause of death
in the United States and worldwide (82). Aging is the biggest risk
factor for the development of CVDs; risk approximately triples
with each decade of life (83). American Heart Association statis-
tics report in 2006 states that 88% of people who died of coronary
heart disease were 65 and older (84).
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We and others have shown that heart expresses the highest level
of HN at both mRNA and protein levels (3, 13, 67). HN is expressed
in the endothelial cell lining of the coronary arteries, human inter-
nal mammary arteries, and sections of the greater saphenous vein
as demonstrated by immune-staining (67). Endogenous HN lev-
els increase after myocardial I/R in mice, and HN is present in the
atherosclerotic plaques of the coronary arteries suggesting a role
for HN in cardiovascular health.
When HNG is administered exogenously, either pre-ischemia
or at the time of reperfusion in a mouse model of myocardial
I/R, there is a dose-dependent decrease in infarct size (3). In addi-
tion, HNG treated mice demonstrated better cardiac function post
MI-R as demonstrated by improved ejection fraction, end-systolic
volume and end-diastolic volume, and cardiac output (3). Further-
more, we also observed that HNG protects cardiac myoblasts from
oxidative stress-induced cell death by acutely increasing activity
of antioxidants through involvement of non-receptor tyrosine
kinases (66).
Widmer et al. reported that human coronary endothelial func-
tion dysfunction is associated with lower systemic HN levels,
introducing a potential diagnostic and/or therapeutic target for
patients with coronary endothelial dysfunction (9). The same
group also demonstrated that the treatment with exogenous HN
protected endothelial cell cultures from Ox-LDL-induced oxida-
tive stress and apoptosis (67). Daily IP injection of HNGF6A for
16 weeks prevented endothelial dysfunction and decreased athero-
sclerotic plaque size in the proximal aorta of Apo-E deficient mice
fed with a high-cholesterol diet, attributable to the reduction in
apoptosis rate and preservation of eNOS activity (68). In the same
mouse model, it was shown that HN attenuates renal microvascu-
lar remodeling, inflammation, and apoptosis in the early stage of
kidney disease, indicating that HN may serve as a novel therapeutic
target to mitigate kidney damage in early atherosclerosis (2). HN
was also demonstrated in the carotid atherosclerotic plaques in
humans, and the expression level of HN was found to be inversely
correlated with the stability of the plaques, i.e., more HN was
present in unstable plaques and patients from stroke subgroup
(47). Whether this suggests a direct role of HN in the forma-
tion or stability of the carotid atherosclerotic plaques needs to be
established.
HN AND METABOLIC EFFECTS
T2DM is one of the most common metabolic diseases and its
prevalence directly correlates with increasing age, peaking at 60–
74. Almost one-third of the elderly have diabetes and three quarters
have diabetes or pre-diabetes (85–87). Age associated changes in
hormonal milieu along with changes in body composition con-
tribute to insulin resistance and increased incidence of diabetes. In
addition, aging is associated with decreased beta-cell proliferative
capacity and enhanced sensitivity to apoptosis (88). Both periph-
eral insulin resistance and impaired insulin secretion contribute
to the pathogenesis of T2DM in aging (86, 89).
Role of HN in glucose homeostasis has been studied using
hyperinsulinemic-euglycemic clamp and hyperglycemic clamp
techniques. Hyperinsulinemic-euglycemic clamp is the gold stan-
dard method to assess in vivo insulin sensitivity and allows assess-
ment of insulin sensitivity specifically at the level of liver and
muscle. During hyperinsulinemic-euglycemic clamps, rats receiv-
ing continuous ICV infusion of HN required higher glucose
infusion rate (GIR) to maintain normoglycemia as a result of
decreased hepatic glucose output and increased glucose uptake
in the skeletal muscle, demonstrating increased insulin sensitiv-
ity. The central action of HN was shown to be mediated via
activation of hypothalamic STAT-3 signaling pathway (43). Our
group also demonstrated that continuous IV infusion of HNGF6A,
HN analog that is stable, potent, and non-IGFBP-3 binding, dur-
ing hyperinsulinemic-euglycemic clamp increased GIR, peripheral
glucose uptake, and suppressed hepatic glucose production. More-
over, HNGF6A, when given as a single IV injection, significantly
lowered the blood glucose in Zucker diabetic fatty rats (43). In
addition, we showed that HN increases glucose uptake into the β
cells, enhances glucose oxidation resulting in an increased GSIS as
demonstrated in vivo, in cultured beta cells and in islets isolated
from wild type and diabetic mice (25). These studies indicate a
role for HN in whole body glucose homeostasis through both
improved insulin action and increased insulin secretion.
Non-obese diabetic mouse is an autoimmune model for T1DM;
the development of diabetes is time-dependent as age correlates
with increased lymphocyte infiltration, decreased beta-cell prolif-
eration, and enhanced sensitivity to glucose-induced β-cell apop-
tosis (88). Treating non-obese diabetic (NOD) mice with HN for
6 weeks normalized glucose tolerance and treatment for 20 weeks
prevented/delayed the onset of diabetes in these mice, secondary
to decreased lymphocyte infiltration in the islets and decreased
apoptosis.
Humanin expression is increased in small arteries along with
succinate dehydrogenase positive staining in MELAS muscle fibers,
and synthesized HN increases cellular ATP levels by directly act-
ing on mitochondria in TE671, a human rhabdomyosarcoma cell
line (46). We also reported that HNGF6A increases mitochon-
dria metabolism and ATP generation in the cultured β cells (25)
showing a role for HN in substrate metabolism.
The prevalence of MS also increases with age (90). MS, poly-
cystic ovarian syndrome, non-alcoholic fatty liver disease, and
dyslipidemia are closely associated with insulin resistance (91, 92).
A future direction would be to determine whether HN has a role
in the pathophysiology of these diseases.
HN AND INFLAMMATION
Obesity, CVD, diabetes, chronic kidney disease, and AD are associ-
ated with a chronic inflammatory state (87, 93–95). Aging per se is
characterized by chronic low-grade systemic inflammation even
in the absence of chronic disease, as the circulating levels of
pro-inflammatory cytokines such as IL-6, tumor necrosis factor
(TNF)-α, and acute phase proteins such as C-reactive protein
(CRP) and serum amyloid A (SAA) increase by two to fourfold in
elderly (96). Chronic inflammation in the elderly may contribute
to multiple diseases, poor physical functioning, and mortality (97).
Therefore, reversing the process of chronic inflammation or, at
least, slowing it down has been an attractive area of research in an
effort to prevent or delay morbidities/mortalities associated with
these conditions.
A role for HN in down-regulation of inflammatory responses
has been demonstrated in vivo and in cell culture systems.
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Miao et al. first observed that HNG ameliorates Aβ25–35-
induced neuro-inflammatory responses by decreasing the level
of IL-6 and TNF-α in mice (73). This important finding
may suggest that in addition to exerting functions through
binding to membrane receptors and intra-cellular molecules,
HNG also offers neuro-protection in AD by altering the
inflammatory response. Zhang and colleagues discovered that
HN attenuates inflammation by down-regulating intra-renal
inflammatory markers of MCP-1, TNF-α, and osteopontin
and reduces macrophage infiltration in hypercholesterolemic
Apo-E deficient mice; thereby decreasing the renal microvas-
cular remodeling, inflammation, and apoptosis in the early
stage of kidney disease (2). Finally, Zhao et al. reported that
treatment of HNG partially suppresses the secretion of pro-
inflammatory cytokines including IL-6, IL-1β, and TNF-α in a
dose-dependent manner in astrocytes induced by lipopolysaccha-
rides (LPS) (51).
HN AND CANCERS
Age-related increase in cancer risk, with leveling off at advanced
ages is well-established (98). HN’s well-known anti-apoptotic
property raised concern among the researchers whether HN con-
tributes to cancer development and helps cancer cell survival.
Maximov et al. hypothesized that HN is an oncopeptide (99),based
on the finding of up-regulation of expression of the mitochondr-
ial 16S rRNA gene in non-Hodgkin’s lymphoma, which potentially
enhances HN expression. Furthermore, HN was immunologically
detected in the serum of some patients with cutaneous T-cell
lymphoma but not in healthy subjects (100). Using the yeast two-
hybrid model, the Maximov group identified MPP8 as a binding
partner for HN (101), which is a previously described oncopro-
tein playing a role in tumor motility and invasion (101); and thus
pointing to the potential role of HN in oncogenesis. Recently,
a suppression subtractive hybridization study showed the over-
expression of HN and isoforms in chemo-resistant tumor gastric
tissues from patients. Utilizing qRT-PCR, the authors confirmed
the increased mRNA levels of HN1, HN3, HN6, and HN10 genes,
suggesting potential role of HN in the development of chemo-
resistance in gastric tumor cells. The limitation of the study, as
noted by the authors, was the lack of protein level measure-
ments that could not be performed due to lack of isoform-specific
antibodies.
Contrary to the potential role of HN in tumorigenesis and
metastasis of the cancer cells, Eriksson and colleagues demon-
strated that, when HNG is administered with bortezomib [pro-
teasome inhibitor currently studied in clinical trials of childhood
leukemia and other cancers that induces apoptosis in growth plate
chondrocytes and impair linear bone growth in treated mice (102–
107)], HNG prevented bortezomib-induced bone growth impair-
ment in mice with human tumor xenograft models (108), without
affecting its chemotherapeutic effects. They also showed in human
tumor xenograft and cell lines that HNG prevented bortezomib-
induced apoptosis by preventing Bax and PARP activation (108).
More interestingly, HNG alone delayed tumor growth and tumor
doubling time in cancers such as medulloblastoma and neurob-
lastoma in vivo (108). The authors speculated that increased Bax
in chondrocytes compared to human neuroblastoma cells could
be the basis for chondrocyte-rescuing effect of HNG following
bortezomib treatment.
The current data on the relationship between HN, tumori-
genesis, and cancer metastasis are not conclusive. More studies
are needed to understand if the changes in expression of HN are
tumor-type specific, whether they are a cause or a compensatory
response and if they affect the response to treatment.
PERSPECTIVE
Since its discovery, HN has been demonstrated to offer benefi-
cial effects in many diseases, many of which are age-related. The
observation that levels of HN decline with age further supports
the role of HN in aging and age-related diseases. Diseases which
were earlier considered age-related such as T2DM are now seen
in much younger ages due to the burgeoning epidemic of obesity.
The role of HN in mitigating the effects of bortezomib on growth
plate chondrocyte apoptosis and islet cell apoptosis on autoim-
mune mouse model of diabetes extend the potential role of HN
beyond the spectrum of age-related diseases. HN and analogs offer
promise as a potential therapeutic option for neurodegenerative
disorders, CVDs, diabetes, and a potential adjunct to chemother-
apy. Further studies are needed to evaluate the pharmacokinetics
and safety profile for long term use. Gain and loss of function
models are necessary to fill the gaps in our current knowledge
and enhance our understanding of the physiological role of this
peptide and its role in various diseases.
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